Safety
RSV infection
ADVERSE EVENTS, EVENTS, RSV INFECTION
After intranasal immunization with Teleflex MAD300, the safety and tolerability of BLB201 were monitored for 6 months. Participants recorded information of local and systemic adverse events (AEs) for 7 days after vaccination (solicited local and systematic events) and unsolicited AEs for 28 days using a memory aid. No serious AE (SAE) assessed as related to vaccine was reported, and no symptomatic RSV infection was reported during the 6-month trial period. In the 1-week period after vaccination, all solicited local AEs that were reported were mild in intensity (grade 1; 